The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I/II study of azacitidine in combination with temozolomide in patients with unresectable or metastatic soft tissue sarcoma or malignant mesothelioma.
Gleneara Elizabeth Bates
No relevant relationships to disclose
Robert N. Taub
No relevant relationships to disclose
Igor Matushansky
No relevant relationships to disclose
Thomas S. Uldrick
No relevant relationships to disclose
Maya Khandker
No relevant relationships to disclose
Yaakov Bressler
No relevant relationships to disclose
Yi Wang
No relevant relationships to disclose